Department of Veterinary, Pathology, Microbiology, and Immu- nology, School of Veterinary Medicine, University of California, Davis, CA). Cells were washed and incubated with FITC- conjugated goat anti-mouse 488 (1:400) for additional 30 min. CD4+ and C8+ T cells were then sorted by FACS (Becton Dickinson). 50,000 total responder T cells (50% CD4 and 50% CD8) were incubated in flat bottom 96-well plates (BECTON DICKINSON cat #353072) with increasing numbers of allogeneic stimulator DCs (0, 1:100, 1:30, 1:10, 1:3, 1:1) in 100 ml supplemented RPMI at 37uC. DCs were incubated in the absence of T cells as controls. Four days later 10 ml BrdU labeling solution (1:100) was added to the media for additional 18 h and BrdU incorporation into all genomic cellular DNA strands was assessed by ELISA following manufacturer’s instructions (Roche-Applied- Science, Cat # 11 647 229 001). Absorbance of the samples was measured without stop solution in an ELISA reader (Spectramax Plus, Molecular Devices) at 370 nm. ELISA Release of IL-6, TNF-a and IFN-c was determined by ELISA following the manufacturer’s protocol (R&D system, Quantikine References 1. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352: 997–1003. 2. Martin V, Liu D, Gomez-Manzano C (2009) Encountering and advancing through antiangiogenesis therapy for gliomas. Curr Pharm Des 15: 353–364. 3. Barth RF (2009) Boron neutron capture therapy at the crossroads: challenges and opportunities. Appl Radiat Isot 67: S3–6. 4. Parker JN, Bauer DF, Cody JJ, Markert JM (2009) Oncolytic viral therapy of malignant glioma. Neurotherapeutics 6: 558–569. 5. Asadi-Moghaddam K, Chiocca EA (2009) Gene- and viral-based therapies for brain tumors. Neurotherapeutics 6: 547–557. 6. Candolfi M, Kroeger KM, Muhammad AK, Yagiz K, Farrokhi C, et al. (2009) Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety. Curr Gene Ther 9: 409–421. 7. Candolfi M, Yagiz K, Foulad D, Alzadeh GE, Tesarfreund M, et al. (2009) Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity. Clin Cancer Res 15: 4401–4414. 8. Muhammad AKMG, Candolfi M, King GD, Yagiz K, Foulad D, et al. (2009) Antiglioma Immunological Memory in Response to Conditional Cytotoxic/ Immune-Stimulatory Gene Therapy: Humoral and Cellular Immunity Lead to Tumor Regression. Clinical Cancer Research 15: 6113–6127. 9. Ali S, King GD, Curtin JF, Candolfi M, Xiong W, et al. (2005) Combined immunostimulation and conditional cytotoxic gene therapy provide long-term survival in a large glioma model. Cancer Res 65: 7194–7204. 10. Curtin J, Liu N, Candolfi M, Xiong W, Assi A, et al. (2009) HMGB1 mediates endogenous TLR2 activation and brain tumor regression. PLoS Medicine 6: e10. 11. Curtin JF, King GD, Barcia C, Liu C, Hubert FX, et al. (2006) Fms-like tyrosine kinase 3 ligand recruits plasmacytoid dendritic cells to the brain. J Immunol 176: 3566–3577. 12. Heidner GL, Kornegay JN, Page RL, Dodge RK, Thrall DE (1991) Analysis of survival in a retrospective study of 86 dogs with brain tumors. J Vet Intern Med 5: 219–226. 13. Foster ES, Carrillo JM, Patnaik AK (1988) Clinical signs of tumors affecting the rostral cerebrum in 43 dogs. J Vet Intern Med 2: 71–74. 14. LeCouteur RA (1999) Current concepts in the diagnosis and treatment of brain tumours in dogs and cats. J Small Anim Pract 40: 411–416. 15. Stonehewer J, Mackin AJ, Tasker S, Simpson JW, Mayhew IG (2000) Idiopathic phenobarbital-responsive hypersialosis in the dog: an unusual form of limbic epilepsy? J Small Anim Pract 41: 416–421. 16. Stoica G, Kim HT, Hall DG, Coates JR (2004) Morphology, immunohisto- chemistry, and genetic alterations in dog astrocytomas. Vet Pathol 41: 10–19. 17. Candolfi M, Curtin JF, Nichols WS, Muhammad AG, King GD, et al. (2007) Intracranial glioblastoma models in preclinical neuro-oncology: neuropatholog- ical characterization and tumor progression. J Neurooncol 85: 133–148. 18. Lipsitz D, Higgins RJ, Kortz GD, Dickinson PJ, Bollen AW, et al. (2003) Glioblastoma multiforme: clinical findings, magnetic resonance imaging, and pathology in five dogs. Vet Pathol 40: 659–669. 19. Orrison WW, Jr., Rose DF, Hart BL, Maclin EL, Sanders JA, et al. (1992) Noninvasive preoperative cortical localization by magnetic source imaging. AJNR Am J Neuroradiol 13: 1124–1128. 20. Braund K (2003) Neoplasia of the Nervous System. In: Braund K, ed. Clinical Neurology in Small Animals - Localization, Diagnosis and Treatment. Human Flt3L Expands Dog DCs ELISA kit cat# CA6000, CATA00 and EL781, respectively). Absorbance was read on a 96-well plate reader (Spectramax Plus, Molecular Devices) at 450 nm and 570 nm to subtract background. Statistical Analysis NCSS Statistical and power analysis software, (Kaysville, Utah, USA) was employed to perform the statistical analysis. MLR curves were analyzed using randomization test. The phagocytosis and ELISA data were analyzed by ANOVA. When data failed normality or Levene’s test for Variance Homogeneity, they were log-transformed. Differences between groups were considered significant at p,0.05. Author Contributions Conceived and designed the experiments: PRL MGC. Performed the experiments: WdX MC CL AGM KY MP PFM JA JDY DK RD JRO GEP KW. Analyzed the data: WdX MC CL AGM KY MP JA JDY DK RD JRO GEP KW PRL MGC. Contributed reagents/materials/analysis tools: PFM JA JDY DK RD JRO GEP. Wrote the paper: WdX MC PRL MGC. IthacaNew York: International Veterinary Information Service (www.ivis.org). pp B02270203. 21. Candolfi M, Kroeger KM, Pluhar GE, Bergeron J, Puntel M, et al. (2007) Adenoviral-mediated gene transfer into the canine brain in vivo. Neurosurgery 60: 167–177; discussion 178. 22. Candolfi M, Pluhar GE, Kroeger K, Puntel M, Curtin J, et al. (2007) Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro. Neuro Oncol 9: 245–258. 23. Oh S, Pluhar GE, McNeil EA, Kroeger KM, Liu C, et al. (2007) Efficacy of nonviral gene transfer in the canine brain. J Neurosurg 107: 136–144. 24. Ciron C, Desmaris N, Colle MA, Raoul S, Joussemet B, et al. (2006) Gene therapy of the brain in the dog model of Hurler’s syndrome. Ann Neurol 60: 204–213. 25. Weber M, Lange C, Gunther W, Franz M, Kremmer E, et al. (2003) Minor histocompatibility antigens on canine hemopoietic progenitor cells. J Immunol 170: 5861–5868. 26. Hagglund HG, McSweeney PA, Mathioudakis G, Bruno B, Georges GE, et al. (2000) Ex vivo expansion of canine dendritic cells from CD34+ bone marrow progenitor cells. Transplantation 70: 1437–1442. 27. Mielcarek M, Kucera KA, Nash R, Torok-Storb B, McKenna HJ (2007) Identification and characterization of canine dendritic cells generated in vivo. Biol Blood Marrow Transplant 13: 1286–1293. 28. Ibisch C, Pradal G, Bach JM, Lieubeau B (2005) Functional canine dendritic cells can be generated in vitro from peripheral blood mononuclear cells and contain a cytoplasmic ultrastructural marker. J Immunol Methods 298: 175–182. 29. Wijewardana V, Sugiura K, Oichi T, Fujimoto M, Akazawa T, et al. (2006) Generation of canine dendritic cells from peripheral blood monocytes without using purified cytokines. Vet Immunol Immunopathol 114: 37–48. 30. Bonnefont-Rebeix C, de Carvalho CM, Bernaud J, Chabanne L, Marchal T, et al. (2006) CD86 molecule is a specific marker for canine monocyte-derived dendritic cells. Vet Immunol Immunopathol 109: 167–176. 31. Catchpole B, Stell AJ, Dobson JM (2002) Generation of blood-derived dendritic cells in dogs with oral malignant melanoma. J Comp Pathol 126: 238–241. 32. King GD, Muhammad AKM, Curtin JF, Barcia C, Puntel M, et al. (2008) Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model. Neuro Oncol 10: 19–31. 33. Wernette CM, Smith BF, Barksdale ZL, Hecker R, Baker HJ (2002) CpG oligodeoxynucleotides stimulate canine and feline immune cell proliferation. Vet Immunol Immunopathol 84: 223–236. 34. Hashimoto M, Asahina Y, Sano J, Kano R, Moritomo T, et al. (2005) Cloning of canine toll-like receptor 9 and its expression in dog tissues. Vet Immunol Immunopathol 106: 159–163. 35. Kurata K, Iwata A, Masuda K, Sakaguchi M, Ohno K, et al. (2004) Identification of CpG oligodeoxynucleotide sequences that induce IFN-gamma production in canine peripheral blood mononuclear cells. Vet Immunol Immunopathol 102: 441–450. 36. House AK, Gregory SP, Catchpole B (2008) Pattern-recognition receptor mRNA expression and function in canine monocyte/macrophages and relevance to canine anal furunuclosis. Vet Immunol Immunopathol 124: 230–240. 37. Im Hof M, Williamson L, Summerfield A, Balmer V, Dutoit V, et al. (2008) Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e11074